Frontiers in Psychiatry,
Год журнала:
2024,
Номер
15
Опубликована: Июль 9, 2024
Background
Research
from
observational
studies
has
demonstrated
a
link
between
Alzheimer’s
disease
(AD)
and
higher
risk
of
cardiovascular
(CVD).
Uncertainty
surrounds
the
exact
genetic
cause
AD
coronary
heart
disease,
particularly
unstable
angina
(UA).
Mendelian
randomization
(MR)
analysis
was
used
to
examine
causal
UA
evaluate
impact
on
UA.
Methods
The
purpose
bidirectional
MR
investigate
exposure
illness
causation.
Genetic
instrumental
variables
for
were
obtained
European
populations
using
genome-wide
association
(GWAS).
primary
conclusions
inverse
variance
weighted
approach
(IVW),
other
sensitivity
techniques
employed.
Sensitivity
analyses
carried
out
heterogeneity
horizontal
pleiotropy
guarantee
accurate
results.
Results
An
elevated
linked
genetically
predicted
(IVW:
OR=3.439,
95%
CI:
1.565-7.555,
P=0.002).
A
substantial
relationship
not
supported
by
any
evidence
in
reverse
study
OR=0.998,
0.995-1.001,
P=0.190).
Various
produced
consistent
revealed
no
discernible
or
pleiotropy.
Conclusions
One
factor
that
we
found
our
trial
AD.
This
highlights
necessity
researching
underlying
molecular
mechanisms
as
well
possibility
creating
individualized
treatment
plans
based
data.
National Science Review,
Год журнала:
2024,
Номер
11(5)
Опубликована: Фев. 27, 2024
ABSTRACT
Virtual
brain
twins
are
personalized,
generative
and
adaptive
models
based
on
data
from
an
individual’s
for
scientific
clinical
use.
After
a
description
of
the
key
elements
virtual
twins,
we
present
standard
model
personalized
whole-brain
network
models.
The
personalization
is
accomplished
using
subject’s
imaging
by
three
means:
(1)
assemble
cortical
subcortical
areas
in
subject-specific
space;
(2)
directly
map
connectivity
into
models,
which
can
be
generalized
to
other
parameters;
(3)
estimate
relevant
parameters
through
inversion,
typically
probabilistic
machine
learning.
We
use
healthy
ageing
five
diseases:
epilepsy,
Alzheimer’s
disease,
multiple
sclerosis,
Parkinson’s
disease
psychiatric
disorders.
Specifically,
introduce
spatial
masks
demonstrate
their
physiological
pathophysiological
hypotheses.
Finally,
pinpoint
challenges
future
directions.
European Journal of Neurology,
Год журнала:
2023,
Номер
31(2)
Опубликована: Сен. 11, 2023
Abstract
Our
aim
is
to
review
the
most
recent
evidence
on
novel
antibody
therapies
for
Alzheimer's
disease
directed
against
amyloid‐β.
This
a
joint
statement
of
European
Association
Neurology
and
Psychiatric
Association.
After
numerous
unsuccessful
endeavors
create
disease‐modifying
therapy
disease,
substantial
consistent
supporting
clinical
effectiveness
monoclonal
antibodies
aimed
at
amyloid‐β
finally
emerging.
The
latest
trials
not
only
achieved
their
primary
objective
slowing
progression
over
several
months
but
also
demonstrated
positive
secondary
outcomes
decrease
in
levels
as
observed
through
positron
emission
tomography
scans.
Taken
whole,
these
findings
mark
significant
breakthrough
by
substantiating
that
reducing
yields
tangible
benefits,
beyond
mere
changes
biomarkers.
Concurrently,
regular
utilization
new
generation
drugs
will
determine
whether
statistical
efficacy
translates
into
clinically
meaningful
improvements.
may
well
signify
dawning
era
development
disease.
Aging and Disease,
Год журнала:
2024,
Номер
unknown, С. 0 - 0
Опубликована: Янв. 1, 2024
Alzheimer's
disease
(AD)
is
an
intricate
neurodegenerative
disorder
characterized
by
the
accumulation
of
misfolded
proteins,
including
beta-amyloid
(Aβ)
and
tau,
leading
to
cognitive
decline.
Despite
decades
research,
precise
mechanisms
underlying
its
onset
progression
remain
elusive.
Cathepsins
are
a
family
lysosomal
enzymes
that
play
vital
roles
in
cellular
processes,
protein
degradation
regulation
immune
responses.
Emerging
evidence
suggests
cathepsins
may
be
involved
AD
pathogenesis.
can
influence
activation
microglia
astrocytes,
resident
cells
brain.
However,
cathepsin
dysfunction
lead
notably
Aβ
tau.
In
addition,
dysregulated
activity
induce
exaggerated
response,
promoting
chronic
inflammation
neuronal
patients
with
AD.
By
unraveling
classification,
functions,
AD's
pathogenesis,
this
review
sheds
light
on
their
involvement
devastating
disease.
Targeting
could
promising
novel
approach
for
mitigating
pathological
processes
contribute
AD,
providing
new
avenues
treatment
prevention.
Exploration of neuroscience,
Год журнала:
2024,
Номер
3(3), С. 255 - 271
Опубликована: Июнь 27, 2024
Alzheimer’s
disease
(AD)
is
a
major
type
of
dementia
and
neurodegenerative
disease,
characterized
by
memory
loss
cognitive
decline.
Over
decades,
significant
efforts
have
been
dedicated
to
finding
its
cause,
pathogenic
mechanisms,
biomarkers
for
early
detection,
clinical
trials
treatment.
Earlier
approved
drugs
mainly
ameliorated
the
symptoms
AD,
until
recent
years
when
two
targeting
amyloid-beta
(Aβ)
protein
were
slow
down
progression
disease.
This
review
article
encompasses
history
drug
development
in
treating
AD
that
failed
succeeded.
Clinicaltrials.org
website
was
systematically
searched
screened
randomized
controlled
with
results
posted
past
10
years.
Among
3,388
trials,
211
interventional
studies
registered
under
met
eligibility.
includes
targets
discovery
such
as
Aβ,
tau,
neurotransmitter
receptors,
neuroinflammation,
multi-target
studies,
repurposing
pharmacological
agents,
non-pharmacological
interventions,
therapy
neuropsychiatric
dementia.
Current
are
ongoing
no
available
yet.
With
vast
choices
investigated,
this
aims
present
some
insights
into
future
design
contribute
our
find
cure.
Current Issues in Molecular Biology,
Год журнала:
2024,
Номер
46(7), С. 6820 - 6835
Опубликована: Июль 2, 2024
Alzheimer's
disease
(AD)
is
one
of
the
most
prevalent
neurodegenerative
diseases
on
a
global
scale.
Historically,
this
pathology
has
been
linked
to
cholinergic
transmission,
and
despite
scarcity
effective
therapies,
numerous
alternative
processes
targets
have
proposed
as
potential
avenues
for
comprehending
complex
illness.
Nevertheless,
fundamental
pathophysiological
mechanisms
underpinning
AD
remain
largely
enigmatic,
with
growing
body
evidence
advocating
significance
muscarinic
receptors
in
modulating
brain's
capacity
adapt
generate
new
memories.
This
review
summarizes
current
state
art
field
receptors'
involvement
AD.
A
specific
key
factor
was
relationship
between
comorbidity
emergence
mechanisms.
Revista Sociedade Científica,
Год журнала:
2025,
Номер
8(1), С. 197 - 203
Опубликована: Янв. 7, 2025
A
Doença
de
Alzheimer
(DA)
é
uma
condição
neurodegenerativa
caracterizada
pela
formação
placas
β-amiloide
(Aβ)
e
emaranhados
neurofibrilares
no
cérebro,
resultando
em
um
declínio
cognitivo
progressivo.
Esta
revisão
examina
as
imunoterapias
mais
recentes
direcionadas
ao
Aβ,
com
ênfase
na
eficácia
anticorpos
monoclonais,
como
Aducanumab,
Lecanemab
Donanemab.
Uma
busca
através
do
PubMed,
utilizando
os
operadores
booleanos
"((anti-amyloid
antibody))
and
((Alzheimer))",
inicialmente
identificou
418
artigos.
Após
a
aplicação
critérios
inclusão
que
exigiam
revisões
sistemáticas
textos
completos
gratuitos,
publicados
entre
2020
2024,
foram
examinados
6
artigos
atenderam
aos
metodológicos
rigorosos
necessários
para
descrever
efeitos
dos
monoclonais
tratamento
da
DA.
Embora
ensaios
clínicos
tenham
mostrado
melhorias
nas
escalas
cognitivas,
o
ADAS-Cog
MMSE,
não
atingiram
nível
relevância
clínica
significativa.
As
terapias
anti-Aβ
representam
avanço
crucial,
espera-se
combinações
futuras
tratamentos
biomarcadores
aprimorem
forma
eficaz
manejo
DA
melhorem
desfechos
pacientes.
Alzheimer s & Dementia,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 8, 2025
Abstract
INTRODUCTION
Plasma‐based
biomarkers
have
shown
promise
for
clinical
implementation,
but
their
accuracy
in
differentiating
Alzheimer's
disease
(AD)
from
syndromes
associated
with
frontotemporal
lobar
degeneration
(FTLD)
has
yet
to
be
fully
investigated.
This
study
assessed
the
potential
of
plasma
differential
diagnosis.
METHODS
cohort
included
374
participants
(96
AD,
278
FTLD).
Plasma
phosphorylated
tau
(p‐tau)
217
,
neurofilament
light
chain
(NfL),
brain‐derived
tau,
glial
fibrillary
acidic
protein,
and
amyloid
beta
1‐42
/
1‐40
ratio
were
measured.
Receiver
operating
characteristic
curve
analyses
diagnostic
accuracy,
a
three‐range
threshold
approach
was
used
stratify
patients
based
on
most
accurate
biomarker.
RESULTS
p‐tau
effectively
distinguished
AD
FTLD,
NfL/p‐tau
showing
superior
accuracy.
The
identified
thresholds
95%
97.5%
sensitivity
specificity,
reducing
need
cerebrospinal
fluid
testing
by
75%
54%,
respectively.
DISCUSSION
are
promising
non‐invasive
suggesting
use
as
alternative
traditional
methods.
Highlights
distinguishes
high
chain/p‐tau
showed
highest
FTLD.
A
reduces
invasive
or
positron
emission
tomography
imaging.
